According to the model of sequential biomarker changes in AD [37], more modest increases in t-tau or p-tau181 levels in cognitively impaired African Americans might result in lower CSF NfL levels and greater hippocampal volumes than similarly impaired Caucasians. This evidence concerns the gene MAPT and Alzheimer disease.